


# Stabilis



## Procainamide hydrochloride



Noms commerciaux

Biocoryl	Espagne
Procanbid	Etats Unis d'Amérique
Pronestyl	Canada, Etats Unis d'Amérique



### Stabilité des solutions

		4 mg/ml	25°C		48			1115
		4 mg/ml	4°C		7			1115
		3 mg/ml	2-8 °C		193			4028
		4 mg/ml	5°C		6			370
		4 & 8 mg/ml	23-25°C		6			370
		8 mg/ml	5°C		24			370



### Stabilité en mélange

		4 mg/ml	23°C		Flumazenil : 0,02 mg/ml	24		187






























### Facteur influençant la stabilité

				705
				1115
				1461
				370
				370



## Compatibilités

			
<input checked="" type="checkbox"/>	Procainamide hydrochloride : 4 mg/ml Amiodarone hydrochloride : 1.8 mg/ml		242
<input checked="" type="checkbox"/>	Procainamide hydrochloride : 3 mg/ml Amiodarone hydrochloride : 4 mg/ml		1036
<input checked="" type="checkbox"/>	Procainamide hydrochloride : 4 mg/ml Argatroban : 1 mg/ml		3764
<input checked="" type="checkbox"/>	Procainamide hydrochloride : 10 mg/ml Bivalirudin : 5 mg/ml		1713
<input checked="" type="checkbox"/>	Procainamide hydrochloride : 1 mg/ml Bretylium tosylate : 1 mg/ml		1193
<input checked="" type="checkbox"/>	Procainamide hydrochloride : 100 mg/ml Caffeine : 10 mg/ml		3964
<input checked="" type="checkbox"/>	Procainamide hydrochloride : 10 mg/ml Cisatracurium besylate : 0.1 >> 5 mg/ml		299
<input checked="" type="checkbox"/>	Procainamide hydrochloride : 10 mg/ml Dexmedetomidine : 4 µg/ml		1712
<input checked="" type="checkbox"/>	Procainamide hydrochloride : 2 mg/ml Diltiazem hydrochloride : 5 mg/ml		198
	<input checked="" type="checkbox"/> <input checked="" type="checkbox"/>		198
<input checked="" type="checkbox"/>	Procainamide hydrochloride : 500 mg/ml Diltiazem hydrochloride : 5 mg/ml		198
<input checked="" type="checkbox"/>	Procainamide hydrochloride : 1 mg/ml Dobutamine hydrochloride : 1 mg/ml		1058
<input checked="" type="checkbox"/>	Procainamide hydrochloride : 8 & 100 mg/ml Dobutamine hydrochloride : 2 mg/ml		1041
<input checked="" type="checkbox"/>	Procainamide hydrochloride : 4 mg/ml Esmolol hydrochloride : 6 mg/ml		174
<input checked="" type="checkbox"/>	Procainamide hydrochloride : 5 mg/ml Famotidine : 0.2 mg/ml		398
<input checked="" type="checkbox"/>	Procainamide hydrochloride : 10 mg/ml Fenoldopam mesylate : 80 µg/ml		1803
<input checked="" type="checkbox"/>	Procainamide hydrochloride : 4 mg/ml Flumazenil : 0,02 mg/ml		187
<input checked="" type="checkbox"/>	Procainamide hydrochloride : 100 mg/ml Heparin sodium : 1 UI/ml	RL	1228
<input checked="" type="checkbox"/>	Procainamide hydrochloride : 100 mg/ml Heparin sodium : 1 UI/ml		1228
<input checked="" type="checkbox"/>	Procainamide hydrochloride : 10 mg/ml Hetastarch : 60 mg/ml		1721
<input checked="" type="checkbox"/>	Procainamide hydrochloride : 100 mg/ml Hydrocortisone sodium succinate : 1 mg/ml		1228
<input checked="" type="checkbox"/>	Procainamide hydrochloride : 100 mg/ml Hydrocortisone sodium succinate : 1 mg/ml	RL	1228
	<input checked="" type="checkbox"/> <input checked="" type="checkbox"/>		1625
<input checked="" type="checkbox"/>	Procainamide hydrochloride : 20 mg/ml Lansoprazole : 0.55 mg/ml		619
<input checked="" type="checkbox"/>	Procainamide hydrochloride : 1 mg/ml Lidocaine hydrochloride : 2 mg/ml	RL	619

	Procainamide hydrochloride : 1 mg/ml Lidocaine hydrochloride : 2 mg/ml		619	
	Procainamide hydrochloride : 100 mg/ml Meropenem : 50 mg/ml		4319	
	Procainamide hydrochloride : 8 mg/ml Metoprolol tartrate : 1 mg/ml		2346	
		Procainamide hydrochloride : 1 >> 4 mg/ml Milrinone lactate : 0.175 & 0.200 mg/ml		191
	Procainamide hydrochloride : 4 mg/ml Netilmicin sulfate : 3 mg/ml		1200	
	Procainamide hydrochloride Pantoprazole sodium		2090	
	Procainamide hydrochloride : 4 mg/ml Ranitidine hydrochloride : 0,5 mg/ml		396	
	Procainamide hydrochloride		1115	
		Procainamide hydrochloride		1461
	Procainamide hydrochloride		705	
	Procainamide hydrochloride : 100 mg/ml Potassium chloride : 40 mEq/l	RL	1228	
	Procainamide hydrochloride : 100 mg/ml Potassium chloride : 40 mEq/l		1228	
	Procainamide hydrochloride : 4 mg/ml Vasopressin : 2 & 4 UI/ml		1801	
	Procainamide hydrochloride : 2 mg/ml Verapamil hydrochloride : 0,08 mg/ml		706	



## Voie d'administration



## Bibliographie

	Type	Source
174	Revue	Schaaf LJ, Robinson DH, Vogel GJ, Wulf BG, Drda KD, Moses JO. Stability of esmolol hydrochloride in the presence of aminophylline, bretylium tosylate, heparin sodium, and procainamide hydrochloride. Am J Hosp Pharm 1990 ; 47: 1567-1571.
187	Revue	Olsen KM, Gurley BJ, Davis GA, Christensen R, Monaghan MS. Stability of flumazenil with selected drugs in 5% dextrose injection. Am J Hosp Pharm 1993 ; 50: 1907-1912.
191	Revue	Riley CM. Stability of milrinone and digoxin, furosemide, procainamide hydrochloride, propranolol hydrochloride, quinidine gluconate, or verapamil hydrochloride in 5% dextrose injection. Am J Hosp Pharm 1988 ; 45: 2079-2091.


198	Revue	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
242	Revue	Campbell S, Nolan PE, Bliss M, Wood R, Mayersohn M. Stability of amiodarone hydrochloride in admixtures with other injectable drugs. Am J Hosp Pharm 1986 ; 43: 917-921.
299	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
370	Revue	Raymond GG, Reed MT, Teagarden JR, Story K, Geberbauer CW. Stability of procainamide hydrochloride in neutralized 5% dextrose injection. Am J Hosp Pharm 1988 ; 45: 2513-2517.
396	Revue	Chilvers MR, Lysne JM. Visual compatibility of ranitidine hydrochloride with commonly used critical-care medications. Am J Hosp Pharm 1989 ; 46: 2057-2058.
398	Revue	Jay GT, Fanikos J, Souney PF. Visual compatibility of famotidine with commonly used critical-care medications during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1556-1557.
619	Revue	Kirschenbaum HL, Aronoff W, Perentesis GP, Plitz GW, Cutie AJ. Stability and compatibility of lidocaine hydrochloride with selected large-volume parenterals and drugs additives. Am J Hosp Pharm 1982 ; 39: 1013-1015.
705	Revue	Lee YC, Malick W, Amann AH, Baaske DM, Shah JJ, Wagenknecht DM, Carter JE. Bretylum tosylate admixture compatibility. II : Dopamine, lidocaine, procainamide, and nitroglycerin. Am J Hosp Pharm 1981 ; 38: 183-187.
706	Revue	Cutie MR. Compatibility of verapamil hydrochloride with other additives. Am J Hosp Pharm 1981 ; 38: 231.
1036	Revue	Hasegawa GR, Eder JF. Visual compatibility of amiodarone hydrochloride injection with other injectable drugs. Am J Hosp Pharm 1984 ; 41: 1379-1380.
1041	Revue	Hasegawa GR, Eder JF. Visual compatibility of dobutamine hydrochloride with other injectable drugs. Am J Hosp Pharm 1984 ; 41: 949-951.
1058	Revue	Kirschenbaum HL, Aronoff W, Piltz GW, Perentesis GP, Cutie AJ. Compatibility and stability of dobutamine hydrochloride with large-volume parenterals and selected additives. Am J Hosp Pharm 1983 ; 40: 1690-1691.
1115	Revue	Baaske DM, Malick AW, Carter JE. Stability of procainamide hydrochloride in dextrose solutions. Am J Hosp Pharm 1980 ; 37: 1050-1052.
1193	Revue	Perentesis GP, Plitz GW, Kirschenbaum HL, Navalakha P, Aronoff W, Cutie AJ. Stability and visual compatibility of bretylum tosylate with selected large-volume parenterals and additives. Am J Hosp Pharm 1983 ; 40: 1010-1012.
1200	Revue	Chaudry IA, Bruely KP, Hurlburt LE, Oden EM. Compatibility of netilmycin sulfate injection with commonly used intravenous injections and additives. Am J Hosp Pharm 1981 ; 38: 1737-1742.
1228	Revue	Allen LV, Stiles ML. Compatibility of various admixtures at Y-injection sites of intravenous administration sets. Part2. Am J Hosp Pharm 1981 ; 38: 380-381.
1461	Revue	Sianipar A, Parkin JE, Sunderland VB. Chemical incompatibility between procainamide hydrochloride and glucose following intravenous admixture. J Pharm Pharmacol 1994 ; 46: 951-955.

1625	Revue	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1712	Revue	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Revue	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Revue	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1801	Revue	Feddema S, Rusho WJ, Tyler LS, Barker B. Physical compatibility of vasopressin with medications commonly used in cardiac arrest. Am J Health-Syst Pharm 2003 ; 60: 1271-1272.
1803	Revue	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
2090	Revue	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2346	Revue	Newland A.M, Mauro V.F, Alexander K.S. Physical compatibility of metoprolol tartrate injection with selected cardiovascular agents Am J Health-Syst Pharm 2009 ; 66: 986-987.
3764	Revue	Jakimczuk P.J, Churchwell M.D, Howard M.S, Mauro V.F, Alexander K.S, Boddu S.H.S. Compatibility of argatroban injection with select antiarrhythmic drugs Am J Health-Syst Pharm 2014 2014; 71: 1831-1832.
3964	Revue	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
4028	Revue	Donnelly R. Stability of Procainamide Injection in Clear Glass Vials and Polyvinyl Chloride Bags. Hosp Pharm 2017 ;52,10 :704-708
4319	Revue	Lessard J-J, Caron E, Schérier H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.

# Stabilis



## Procainamide hydrochloride



### Stabilité des préparations

		Sirop de cerise (pH6) >> 30 ml	4-6°C		180			2501
		Sirop de cerise (pH6) >> 30 ml	4-6°C		180			2501
		Sirop de cerise (pH6) >> 30 ml	4-6°C		180			2501
		OraPlus® / OraSweet® (1:1) >> 120 ml	25°C		60			2441
		OraPlus® / OraSweet SF® (1:1) >> 120 ml	25°C		60			2441
		Sirop de cerise >> 120 ml	25°C		60			2441
		OraPlus® / OraSweet® (1:1) >> 120 ml	25°C		60			2441
		OraPlus® / OraSweet SF® (1:1) >> 120 ml	25°C		60			2441
		Sirop de cerise >> 120 ml	5°C		60			2441



### Compatibilités

	Procainamide hydrochloride : 8 mg/ml Furosemide : 10 mg/ml		3210	



## Bibliographie

	Type	Source
2441	Revue	Allen LV, Jr, Erickson MA, Stability of ketoconazole, metolazone, metronidazole, procainamide hydrochloride, and spironolactone in extemporaneously compounded oral liquids Am J Health-Syst Pharm 1996 ; 53: 2073-2078.
2501	Revue	Metras JI, Swenson CF, McDermott MP. Stability of procainamide hydrochloride in an extemporaneously compounded oral liquid Am J Hosp Pharm 1992 ; 49: 1720-1724.
3210	Revue	Jasti Bhaskara R, Saraf Poonam. Compatibility of Parenteral Furosemide with Seventeen Secondary Drugs Used in Standard Concentrations. Int J Pharm Compound 2011 ; 15, 3: 259-261.



# Dictionnaire

Antiarythmique	Injectable
Noms commerciaux	Stabilité des solutions
Contenant	Molécule
Concentration	Température
Conservation	Durée de stabilité
Biosimilaire	Données conflictuelles
Bibliographie	Verre
Eau pour préparation injectable	Non précisée
Heure	A l'abri de la lumière
Jour	Polyvinyl chlorure
Chlorure de sodium 0,9%	Glucose 5%
Stabilité en mélange	Solvant
Molécule	Lumière
Facteur influençant la stabilité	Provoque
Dégradation	Augmentation
Diminution	Compatibilités
Compatible	NaCl 0,9% ou glucose 5%
Aucun	Turbidité immédiate
Incompatible	<b>RL</b> Ringer lactate
Solvant spécifique	Précipitation immédiate
Instabilité chimique	Voie d'administration
Intraveineuse	Perfusion intraveineuse
Intramusculaire	Bibliographie
Solution buvable	Stabilité des préparations
Origine	Excipient
Gélules	Flacon plastique
Dictionnaire	